
    
      The purpose of this study is to assess the safety and tolerability profile of ATYR1940 in the
      treatment of adult patients with molecularly defined genetic muscular dystrophies, and to
      additionally explore the pharmacokinetics and biologic activity of ATYR1940 in adult patients
      with molecularly defined genetic muscular dystrophies. Patients who successfully complete a
      parent study (NCT02239224) are eligible for enrollment into this long-term extension study.
    
  